<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04601324</url>
  </required_header>
  <id_info>
    <org_study_id>Allergic Rhinitis Protocol</org_study_id>
    <nct_id>NCT04601324</nct_id>
  </id_info>
  <brief_title>Allergic Rhinitis Combination Pharmacotherapy Efficacy Study</brief_title>
  <official_title>Randomized Controlled Trial Evaluating Combination Rupatadine and Fluticasone Propionate Compared to Azelastine Hydrochloride and Fluticasone Propionate in Treating Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Paul's Sinus Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Paul's Sinus Centre</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combination pharmacotherapy is often used in people who have failed mono-therapies in&#xD;
      managing their bothersome allergic rhinitis symptoms . However, there is a paucity of&#xD;
      research indicating the most effective combination therapies in managing allergic rhinitis.&#xD;
      This study aims to evaluate the efficacy of oral antihistamine (rupatadine) combined with&#xD;
      nasal steroid (fluticasone propionate) compared to a well-studied combination therapy of&#xD;
      nasal steroid with nasal antihistamine spray (MP-AzeFlu).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allergic rhinitis is a common inflammatory disorder of the nose that is increasing in&#xD;
      prevalence worldwide. Symptoms of allergic rhinitis has a significant negative impact on an&#xD;
      individual's quality of life. When the symptoms are not well managed with allergen avoidance&#xD;
      and first line pharmacotherapies, patients often resort to using a combination of&#xD;
      medications. Physicians may recommend combination therapies to patients with&#xD;
      moderate-to-severe allergic rhinitis, however, there is a scarcity of research indicating&#xD;
      efficacy of combination therapy use. The investigators of this study aim to evaluate the&#xD;
      efficacy of combining oral antihistamine (rupatadine) with nasal steroid (fluticasone&#xD;
      propionate) compared to a well-studied combination therapy of nasal steroid with nasal&#xD;
      antihistamine spray (MP-AzeFlu) in people suffering from medium-to-severe allergic rhinitis.&#xD;
      Oral rupatadine is a potent antihistamine and platelet activating factor (PAF) antagonist,&#xD;
      which has not been studied in combination therapy in allergic rhinitis. Fluticasone&#xD;
      propionate is a well established, first line nasal steroid.&#xD;
&#xD;
      Adults 19 years or older, seen in the Principal Investigator's office presenting with&#xD;
      moderate-to-severe allergic rhinitis will be identified by the principal investigator and&#xD;
      invited to participate in this prospective study. Patients will be recruited into the study&#xD;
      in a consecutive manner. After providing consent, baseline characteristics will be collected.&#xD;
      The investigator aims to recruit 51 patients in each study group respectively. Descriptive&#xD;
      statistics will be used to analyze the baseline characteristic data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Reflective Total Nasal Symptom Score (TNSS)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Score range of 0 to 12, higher scores indicate worse symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Individual reflective nasal symptoms score (iTNSS)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Score range of 0 to 12, higher scores indicate worse symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in reflective total ocular symptoms score (rTOSS)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Score range of 0 to 12, higher scores indicate worse symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Score range of 0 to 168, split into 7 sections, higher the score relates to more negative impact on QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>2 weeks</time_frame>
    <description>Patient reported adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Dymista (Azelastine hydrochloride and fluticasone propionate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive standard of care, which includes twice daily MP-AzeFlu nasal spray (formulation of 137 mg of azelastine hydrochloride and 50 mcg of fluticasone propionate per spray) separated by 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone Propionate and Rupatadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will administer fluticasone propionate nasal spray once daily (2 sprays in each nostril, 50 mcg fluticasone propionate per spray)and 1 tablet of Rupatadine (10mg) once daily in the morning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone Propionate</intervention_name>
    <description>Participants will be required to use fluticasone propionate nasal spray twice daily.</description>
    <arm_group_label>Fluticasone Propionate and Rupatadine</arm_group_label>
    <other_name>Flonase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelastine hydrochloride and fluticasone propionate</intervention_name>
    <description>Participants will be required to administer twice daily MP-AzeFlu nasal spray (formulation of 137 mg of azelastine hydrochloride/50 mg of fluticasone propionate) separated by 12 hours.</description>
    <arm_group_label>Dymista (Azelastine hydrochloride and fluticasone propionate)</arm_group_label>
    <other_name>Dymista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rupatadine</intervention_name>
    <description>Rupatadine once daily for a total of 2 weeks.</description>
    <arm_group_label>Fluticasone Propionate and Rupatadine</arm_group_label>
    <other_name>RUPALL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient over the age of 18&#xD;
&#xD;
          2. Positive allergy skin prick test that diagnose AR&#xD;
&#xD;
          3. Persistent and Moderate-to-Severe AR (Persistent symptoms for more than 6 weeks and&#xD;
             suffers from abnormal sleep, impairment of daily activities, work-school problems, or&#xD;
             has troublesome symptoms; TNSS of at least 8/12)&#xD;
&#xD;
          4. Negative CT sinus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-Allergic Rhinitis patients will be excluded from this study.&#xD;
&#xD;
          2. Participants who are pregnant or lactating&#xD;
&#xD;
          3. Hypersensitivity to FP, MP-AzeFlu, or Rupatadine&#xD;
&#xD;
          4. Superficial or moderate nasal erosion, nasal mucosal ulceration or nasal septum&#xD;
             perforation, who had nasal surgery within the last year, had significant pulmonary&#xD;
             disease (excluding intermittent asthma)&#xD;
&#xD;
          5. Participants who had inferior turbinate reduction surgery&#xD;
&#xD;
          6. Participants who smoke&#xD;
&#xD;
          7. Not able to read and understand the consent form&#xD;
&#xD;
          8. Patients suffering from nonallergic rhinitis (eg. vasomotor, infectious, or&#xD;
             drug-induced rhinitis) or with a negative skin prick test will not be included&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Paul's Sinus Centre</investigator_affiliation>
    <investigator_full_name>Dr. Andrew Thamboo, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Allergic Rhinitis</keyword>
  <keyword>Oral Antihistamine</keyword>
  <keyword>Nasal Steroid</keyword>
  <keyword>Nasal Antihistamine Spray</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
    <mesh_term>Azelastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

